scholarly journals Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update

Oncotarget ◽  
2017 ◽  
Vol 8 (54) ◽  
pp. 93258-93278 ◽  
Author(s):  
Jia-Zhou Ye ◽  
Yan-Yan Wang ◽  
Tao Bai ◽  
Jie Chen ◽  
Bang-De Xiang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Portal Vein ◽  
Cancer Treatment ◽  
Surgical Resection ◽  
Tumor Thrombus ◽  
Asia Pacific ◽  
Pacific Region ◽  
Asia Pacific Region ◽  
Treatment Algorithms

scholarly journals Hepatocellular carcinoma in the Asia pacific region

2009 ◽  
Vol 24 (3) ◽  
pp. 346-353 ◽  
Author(s):  
Man-Fung Yuen ◽  
Jin-Lin Hou ◽  
Anuchit Chutaputti
Keyword(s):  
Hepatocellular Carcinoma ◽  
Asia Pacific ◽  
Pacific Region ◽  
Asia Pacific Region

scholarly journals In-hospital Mortality after Surgical Resection in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

2019 ◽  
Vol 10 (1) ◽  
pp. 72-80 ◽  
Author(s):  
Xiu-Ping Zhang ◽  
Yu-Zhen Gao ◽  
Zhen-Hua Chen ◽  
Kang Wang ◽  
Yu-Qiang Cheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Hospital Mortality ◽  
Surgical Resection ◽  
Tumor Thrombus ◽  
Portal Vein Tumor Thrombus

scholarly journals Environmental contributions to gastrointestinal and liver cancer in the Asia-Pacific region

2017 ◽  
Vol 33 (1) ◽  
pp. 111-120 ◽  
Author(s):  
Kwang-Pil Ko ◽  
Aesun Shin ◽  
Sooyoung Cho ◽  
Sue K Park ◽  
Keun-Young Yoo
Keyword(s):  
Liver Cancer ◽  
Asia Pacific ◽  
Pacific Region ◽  
Asia Pacific Region

scholarly journals Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia–Pacific Region: A Review and Multidisciplinary Expert Opinion

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2626
Author(s):  
Sadahisa Ogasawara ◽  
Su-Pin Choo ◽  
Jiang-Tao Li ◽  
Changhoon Yoo ◽  
Bruce Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Expert Opinion ◽  
Kinase Inhibitors ◽  
Asia Pacific ◽  
Advanced Hepatocellular Carcinoma ◽  
Pacific Region ◽  
Patient Access ◽  
Asia Pacific Region ◽  
First Line ◽  
Systemic Treatments

Hepatocellular carcinoma (HCC) is the fourth most common driver of cancer-related death globally, with an estimated 72% of cases in Asia. For more than a decade, first-line systemic treatments for advanced or unresectable HCC were limited to the multi-targeted kinase inhibitors sorafenib and, more recently, lenvatinib. Now, treatment options have expanded to include immunotherapy, as exemplified by the immune checkpoint inhibitor (ICI) atezolizumab combined with the antiangiogenic agent bevacizumab. Additional combinations of ICIs with kinase inhibitors, other ICIs, or antiangiogenic agents are under investigation, further supporting the new era of immunotherapy for first-line treatment of advanced or unresectable HCC. We describe this evolving landscape and provide expert opinion on therapeutic best practices in the Asia–Pacific region, where different costs of, and patient access to, treatment are a challenge. With the combination of atezolizumab plus bevacizumab likely to become the clinical standard of care, optimising treatment sequence and ensuring patient access to newer therapies remain priorities. Cost containment and treatment sequencing may be facilitated by characterisation of predictive positive and negative biomarkers. With these considerations in mind, this review and expert opinion focused on advanced HCC in the Asia–Pacific region offers perspectives of multiple stakeholders, including physicians, payer systems, and patients.

Sign in / Sign up

Export Citation Format

Share Document